[EN] SORTILIN INHIBITORS [FR] INHIBITEURS DE LA SORTILINE
摘要:
The present invention is directed towards compounds of formula (I), capable of binding to sortilin and thereby useful as sortilin inhibitors in the treatment of diseases, disorders and conditions associated with sortilin activity and binding of ligands, such as progranulin, to sortilin.
Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors
申请人:Nilsson Peter
公开号:US20120004244A1
公开(公告)日:2012-01-05
There is provided compounds of formula I,
wherein E
1
, E
2a
, E
2b
, E
2c
, E
4
, D
1
, D
2
, D
3
, L
1
, Y
1
, L
2
and Y
2
have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C
4
synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation.
CELL NECROSIS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF
申请人:Shanghai Institute of Organic Chemistry, Chinese
Academy of Sciences
公开号:EP3816163A1
公开(公告)日:2021-05-05
Provided by the present application are a cell necrosis inhibitor, a preparation method therefor and a use thereof; in particular, provided by the present application is an inhibitor of cell necrosis and/or human receptor-interacting protein 1 kinase (RIP1). The inhibitor has a structure as shown in the following formula I. The compound and a composition comprising same may be used to prevent and/or treat diseases involving cell death and/or inflammation.
本申请提供了一种细胞坏死抑制剂、其制备方法及其用途;特别是,本申请提供了一种细胞坏死和/或人类受体相互作用蛋白1激酶(RIP1)抑制剂。该抑制剂具有如下式 I 所示的结构。该化合物和包含该化合物的组合物可用于预防和/或治疗涉及细胞死亡和/或炎症的疾病。
US3940403A
申请人:——
公开号:US3940403A
公开(公告)日:1976-02-24
US3994908A
申请人:——
公开号:US3994908A
公开(公告)日:1976-11-30
[EN] SORTILIN INHIBITORS<br/>[FR] INHIBITEURS DE LA SORTILINE
申请人:[en]SORTINA PHARMA AB
公开号:WO2023101595A1
公开(公告)日:2023-06-08
The present invention is directed towards compounds of formula (I), capable of binding to sortilin and thereby useful as sortilin inhibitors in the treatment of diseases, disorders and conditions associated with sortilin activity and binding of ligands, such as progranulin, to sortilin.